IPIX

American Fair Credit Council Names Industry Veterans as New Board Members

Retrieved on: 
Wednesday, September 7, 2022
Professional Services, Other Professional Services, Finance, Consulting, Banking, Personal Finance, Boston University School of Law, VP, U.S. Department of Defense Strategy for Operating in Cyberspace, Technology, CEO, Conduct, University of Cambridge, Farm Credit Council, JD, Solution, Veteran, Duke University, IPIX, AFCC, Privacy, Georgetown University Law Center, United States Department of Justice Antitrust Division, Social, Stanford University, Founder, Knowledge, FDR, Industry, Growth, Bank

The American Fair Credit Council (AFCC) announced today that Sean Fox, President of Freedom Debt Relief (FDR), and Sanj Goyle, Entrepreneur-In-Residence at Priority Technology Holdings (PRTH), will join the organization's Executive Board of Directors.

Key Points: 
  • The American Fair Credit Council (AFCC) announced today that Sean Fox, President of Freedom Debt Relief (FDR), and Sanj Goyle, Entrepreneur-In-Residence at Priority Technology Holdings (PRTH), will join the organization's Executive Board of Directors.
  • "On the AFCC Board, I will strive to offer advice and counsel to help the AFCC and its members continue providing a critical financial service."
  • "The AFCC Executive Board is leading many vital projects that continue to improve debt resolution for the hundreds of thousands of Americans our industry serves," said Sean Fox.
  • The American Fair Credit Council (AFCC) is the national association of professional debt resolution companies.

Indigo Technologies Debuts Model of FLOW and FLOW PLUS at ACT Expo 2022, Highlighting its Fleet, Ridesharing, and Delivery EVs

Retrieved on: 
Monday, May 9, 2022
ACT, Board, University of Memphis, Economics, Juancho E. Yrausquin Airport, FLOW, FLEET, Competition (economics), Light, Vice, OEM, Director, Time, Central Waqf Council, Ridesharing, EVS, Lucid Motors, American Council, Veteran, Mobility, Efficiency, IPIX, LOS, Motorola, View, The Chartered Institute of Ergonomics and Human Factors, CEO, Ownership, Transport, Multimedia, Management, Airline, Meanings of minor planet names: 3001–4000, Adviser, Indigo, Porsche, Technology, Audi, Nortel

LOS ANGELES, May 9, 2022 /PRNewswire/ -- Indigo Technologies, an automotive OEM building a whole new class of smoother, roomier and more affordable light EVs for fleets, delivery, and rideshare, today revealed the full-size model of the Indigo FLOW™ and FLOW PLUS™ at the Advanced Clean Transportation (ACT) Expo (Booth #548) in Long Beach, California, May 9-11, 2022. 

Key Points: 
  • We are very excited to showcase the Indigo FLOW and FLOW PLUS.
  • Indigo EVs' unmatched rider ergonomics and unit economics are enabled by its patented robotic wheels that free up more cabin space while providing superior ride quality.
  • "We are very excited to showcase the Indigo FLOW and FLOW PLUS," says Will Graylin , CEO of Indigo.
  • Indigo is delivering a whole new class of smoother, roomier and more affordable light EVs designed for rideshare & delivery.

Yoshi Builds Out Executive Team With Mobility Industry Veteran Amidst Rapid Growth

Retrieved on: 
Tuesday, April 5, 2022
Yoshi, Business development, BA, University, NFL, LinkedIn, Investment, Syniverse, Marketing, NBA, Multimedia, Original equipment manufacturer, CEO, Senior, List of NBA All-Stars, IPIX, Y Combinator, MBA, Lewis, General Motors, Motorola, Facebook, Solution, YouTube, OnStar, IPO, Instagram, Social media, ExxonMobil, Silicon, Public relations, Management, Amazon, Bridgestone

NASHVILLE, Tenn., April 5, 2022 /PRNewswire/ -- Yoshi, the leading tech enabled last-mile delivery platform for car care, announced today that Ed Lewis has joined the company as Chief Commercial Officer. Lewis will lead growth initiatives and oversee sales and business development for the company's corporate and fleet businesses. The newly created leadership position will be based in Nashville, and the announcement comes on the heels of Bridgestone's investment in the company earlier this year (joining strategic investors General Motors and ExxonMobil).

Key Points: 
  • Lewis will lead growth initiatives and oversee sales and business development for the company's corporate and fleet businesses.
  • Lewis joins Yoshi from Arrive Mobility where he served as the company's Senior Vice President of Business Development.
  • Arrive is a leading provider of last-mile mobility and parking solutions reaching 200 million drivers.
  • "He has an excellent reputation across the mobility sector as an effective leader who has developed products and business cases that drive profitable business growth.

Last Patient Last Visit Completed in Innovation Pharmaceuticals’ Phase 2 Clinical Trial of Brilacidin for COVID-19; Trial Database Undergoing Review in Preparation for Database Lock

Retrieved on: 
Thursday, August 12, 2021
U.S. Securities and Exchange Commission, Clinical trial, Data management, Government, Company, IPIX, Private Securities Litigation Reform Act, Cell culture, OTCQB, Inflammation, COVID-19, Infection, GLOBE, Research, Inhibitor, Anton Bakov, Coronavirus, Security (finance), Patient, Risk, Sale, Cancer, Severe acute respiratory syndrome coronavirus 2, Biostatistics, Pharmaceutical industry

Full enrollment in the 120-patient clinical trial was completed in early June 2021.

Key Points: 
  • Full enrollment in the 120-patient clinical trial was completed in early June 2021.
  • Following database lock and transfer to the biostatistics vendor, analysis of the unblinded data from the clinical trial will begin to assess Brilacidins performance, against placebo, across primary, secondary, and other endpoints.
  • Topline results are anticipated to be available one week after database lock, with full analysis to follow.
  • Our team is as excited as anyone to learn the results of our Brilacidin COVID-19 clinical trial.

Innovation Pharmaceuticals – Clinical Trial Testing of Brilacidin Against SARS-CoV-2 (COVID-19) Targeted to Commence Q4 2020

Retrieved on: 
Monday, July 13, 2020
IPIX, Panorama software

WAKEFIELD, Mass., July 13, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (the Company), a clinical stage biopharmaceutical company, today provides perspectives on the planned clinical trial testing of Brilacidin, administered intravenously (IV), for the treatment of COVID-19.

Key Points: 
  • WAKEFIELD, Mass., July 13, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (the Company), a clinical stage biopharmaceutical company, today provides perspectives on the planned clinical trial testing of Brilacidin, administered intravenously (IV), for the treatment of COVID-19.
  • As previously released, manufacturing steps are now underway to prepare Brilacidin for COVID-19 clinical trial use, including the sourcing of materials and making of sterile IV drug product.
  • In parallel to these manufacturing efforts, the Company has drafted a study protocol toward initiating a planned Phase 2 trial of Brilacidin for COVID-19.
  • Given the continuing coronavirus pandemic, and especially in light of surging cases in the United States, the Company is looking to start a clinical trial with Brilacidin for COVID-19 treatment in Q4 2020.

Innovation Pharmaceuticals Receives Data Supporting Brilacidin’s Direct Inhibition of SARS-CoV-2, the Novel Coronavirus Responsible for COVID-19

Retrieved on: 
Wednesday, April 1, 2020
Viruses, Zoonoses, Coronaviridae, Animal virology, In Saudi Arabia, Coronavirus, Middle East respiratory syndrome-related coronavirus, CoV, OTC Markets Group, Severe acute respiratory syndrome-related coronavirus, IPIX, Severe acute respiratory syndrome

WAKEFIELD, Mass., April 01, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (the Company), a clinical stage biopharmaceutical company, announced today it has received data supporting Brilacidins direct inhibition of SARS-CoV-2, the novel coronavirus responsible for COVID-19.

Key Points: 
  • WAKEFIELD, Mass., April 01, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (the Company), a clinical stage biopharmaceutical company, announced today it has received data supporting Brilacidins direct inhibition of SARS-CoV-2, the novel coronavirus responsible for COVID-19.
  • The Company is reviewing data received yesterday and anticipates more data will be forthcoming.
  • Brilacidins robust antimicrobial properties might also help fight secondary bacterial infections, which can co-present in patients with COVID-19.
  • A more complete description of these risk factors is included in the Companys filings with the Securities and Exchange Commission.

Innovation Pharmaceuticals Provides Scientific Rationale and Clinical Development Perspectives for Brilacidin as a Potential Novel Coronavirus COVID-19 Treatment

Retrieved on: 
Monday, March 2, 2020
Medical specialties, Medicine, Viruses, Peripheral membrane proteins, Defensins, Antimicrobial peptides, Brilacidin, Guanidines, Middle East respiratory syndrome-related coronavirus, Coronavirus, IPIX

WAKEFIELD, Mass., March 02, 2020 (GLOBE NEWSWIRE) -- March 2, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (the Company), a clinical stage biopharmaceutical company, is pleased to provide scientific rationale and clinical development perspectives for Brilacidin, the Companys defensin mimetic drug candidate, as a potential novel coronavirus (COVID-19) treatment.

Key Points: 
  • WAKEFIELD, Mass., March 02, 2020 (GLOBE NEWSWIRE) -- March 2, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (the Company), a clinical stage biopharmaceutical company, is pleased to provide scientific rationale and clinical development perspectives for Brilacidin, the Companys defensin mimetic drug candidate, as a potential novel coronavirus (COVID-19) treatment.
  • Linked below is an overview document (a downloadable pdf) summarizing the scientific rationale for developing Brilacidin as a potential COVID-19 treatment, both as an intravenous medication and as a possible vaccine.
  • Background and Scientific Rationale for Brilacidin as a Potential Novel Coronavirus (COVID-19) Treatment (March 1, 2020)
    Defensins are small antimicrobial peptides expressed widely in the animal kingdom that serve as the first line of defense against foreign invasion of the body.
  • The Company has also submitted a preliminary summary of Brilacidins potential as a novel coronavirus treatment to the U.S.

Innovation Pharmaceuticals Announces Dose Escalation

Retrieved on: 
Friday, January 17, 2020
Life sciences, Articles, Pharmaceutical industry, Health, Brilacidin, Medication, IPIX, Biopharmaceutical

WAKEFIELD, Mass., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (the Company), a clinical stage pharmaceutical company, announced today that the Company has received agreement from the studys Dose Escalation Committee (DEC) to progress dosing to the second cohort in its Phase 1 trial to investigate the use of delayed release tablets for colonic delivery of Brilacidin in healthy volunteers.

Key Points: 
  • WAKEFIELD, Mass., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (the Company), a clinical stage pharmaceutical company, announced today that the Company has received agreement from the studys Dose Escalation Committee (DEC) to progress dosing to the second cohort in its Phase 1 trial to investigate the use of delayed release tablets for colonic delivery of Brilacidin in healthy volunteers.
  • The Principal Medical Investigator and Sponsor agreed it acceptable to increase the dose of Brilacidin for administration to a second cohort per trial design.
  • Innovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious disease, and dermatologic diseases.
  • A more complete description of these risk factors is included in the Companys filings with the Securities and Exchange Commission.